Sol-Gel Technologies reports Q3 EPS (21c) vs (15c) last year

Reports Q3 revenue $213,000 vs $261,000 last year. “We are on track to begin pivotal Phase 3 testing for our Breakthrough-designated, Orphan Drug candidate, SGT-610, or patidegib, for the prevention of basal cell carcinoma in subjects having Gorlin syndrome, which we are planning to initiate this quarter. We anticipate this candidate will have a market potential of over $300 million as a first-ever therapy in a patient population that currently has no approved therapies,” stated Alon Seri Levy, Ph.D., Chief Executive Officer of Sol-Gel.